Abstract 4094
Background
In pediatric patients (pts) with localized osteosarcoma, cure rates higher than 60% have been reported. A chemotherapy (CT) regimen frequently suggested as standard in this scenario is the three-drug regimen MAP (methotrexate [MTX], doxorubicin, and cisplatin). However, the addition of MTX remains controversial, especially in adult pts in whom high-grade toxicities are frequent. We aimed to evaluate the outcomes of adult pts with localized osteosarcoma after treatment with CT without MTX.
Methods
A single-center cohort of adult pts with high-grade osteosarcoma treated with CT without MTX was retrospectively evaluated. Pts were treated between 2007 and 2018. Overall survival (OS) was calculated from the date of diagnosis to death. Recurrence-free survival (RFS) was time from diagnosis to recurrence or death. Kaplan-Meier method was used for survival analysis. Prognostic factors were evaluated with Cox regression.
Results
A total of 97 consecutive adult pts with osteosarcoma were studied. Median age was 27 years (range 16 – 69). Primary tumor site was extremity in 79.4% of pts (N = 77), and axial in 20.6% (N = 20). Most pts (N = 61; 63%) presented localized resectable disease, while 36 (37%) had unresectable or metastatic disease. Among pts with localized resectable disease, 56 (91%) pts received neoadjuvant/ adjuvant CT without MTX: 48 (86%) received cisplatin and doxorubicin; 8 (14%) received other combinations of cisplatin, doxorubicin, ifosfamide, and/or etoposide. With a median follow-up of 34 months, 3-year and 5-year RFS rates were 42.4% (IC 95% 28 – 55%) and 37.1% (IC 95% 23 – 50%). 3-year and 5-year OS rates were 81.6% (95% CI, 67% – 90%) and 67.3% (95% CI, 48% – 80%). Median RFS and OS were 31.8 months and not reached, respectively. The only factor associated with OS was the number of neoadjuvant/ adjuvant CT cycles (≥ 6 vs < 6 cycles: HR 0.25, 95% CI 0.07 – 0.83, P = 0.025).
Conclusions
Adult pts with localized osteosarcoma treated with CT without MTX had unfavorable survival outcomes in comparison with the literature for pediatric pts. A number of neoadjuvant/ adjuvant CT cycles of 6 or more was associated with superior OS. Improving therapeutic approaches for adult pts is of utmost importance to achieve better results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4925 - Prognostic role of CD73 in metastatic Non Small Cell Lung Cancer according to the presence of driver alterations
Presenter: Giulia Galli
Session: Poster Display session 1
Resources:
Abstract
785 - JAK-STAT inhibitor overcomes interferon γ-reduced, NK cell-mediated cytotoxicity in non-small-cell lung cancer cells
Presenter: Riki Okita
Session: Poster Display session 1
Resources:
Abstract
2326 - Low LATS2 expression is associated with poor prognosis in non small cell lung cancer
Presenter: Si-hyong Jang
Session: Poster Display session 1
Resources:
Abstract
5960 - Application of ESCAT and OncoKB scales in Liquid biopsy (LB) in Advanced NSCLC patients (pts): Is it feasible and reliable?
Presenter: Michael McCusker
Session: Poster Display session 1
Resources:
Abstract
4855 - IDH1R132H mutation induces a less aggressive phenotype of glioma cells and affects the radiosensitivity by interacting with Wnt/β-catenin signaling
Presenter: Xuetao Han
Session: Poster Display session 1
Resources:
Abstract
2641 - Impact of Angiopoietin-2 on glioblastoma response to combined chemo-radiotherapy
Presenter: Charly Helaine
Session: Poster Display session 1
Resources:
Abstract
5743 - The Discovery of RNA-aptamers That Selectively Bind and Inhibit Glioblastoma Stem Cells by targeting EphA2
Presenter: Alessandra Affinito
Session: Poster Display session 1
Resources:
Abstract
4160 - Impact of tumor reoxygenation by nanoparticles on Tumor Associated Macrophages (TAMs)
Presenter: Aurélie Ferré
Session: Poster Display session 1
Resources:
Abstract
2474 - Prognostic significance of c-Rel/p50 heterodimer in the tumor microenvironment of uveal melanoma
Presenter: Seema Kashyap
Session: Poster Display session 1
Resources:
Abstract
1769 - Synergistic role of BAP1 and DNA damage response pathway in uveal melanoma and its prognostic significance.
Presenter: JAYANTI JHA
Session: Poster Display session 1
Resources:
Abstract